

Anti-PCSK9 Antibody (Alirocumab Biosimilar)

Cat. No. AB472




Description	
Reactivities	Human/Cynomolgus
Target	PCSK9
Isotype	Human IgG1-Kappa
Conjugation	Unconjugated
ExpressSystem	HEK293
Applications	ELISA
MolecularWeight	50.68 kDa and 22.57 kDa.
Recommended Dilution Buffer	PBS (pH 7.4), contains no stabilizers or preservatives.
Purification	protein A
Sterility	0.2 µM filtered
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage	
Formulation	PBS, 10% glycerol (pH 7.4)
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1. The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.	

Assay Data


Bis-Tris PAGE



Alirocumab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data




The purity of Alirocumab Biosimilar is greater than 95% as determined by SEC-HPLC.

ELISA Data

Alirocumab Biosimilar ELISA

0.2µg Human PCSK9, His Tag Per Well



Immobilized Human PCSK9, His Tag at 2µg/ml (100µl/well) on the plate. Dose response curve for Alirocumab Biosimilar with the EC50 of 0.13µg/ml determined by ELISA.